AbbVie News Center

Home /

Latest news

March 04, 2026

ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS

Data shows a rise in specific treatment demand; a shift in patient consultation and the rising role of facial volume restoration 67% of patients say MWL treatment changed their goals toward...

March 03, 2026

AbbVie to Present at the Leerink Partners Global Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will participate in a fireside chat at 10:20 a.m. Central Time. A...

March 02, 2026

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI®) achieved superiority for the co-primary and ranked secondary endpoints at week 12...

AbbVie on

Looking for more news from AbbVie? Follow us on social media.

Press Kits

Our press kits are designed to provide journalists with a broad range of background information on our company.

Image library

Our media library provides you with our official AbbVie media including our logo, building and leaders.

Stay up to date on recent news, articles, and more.

Month Year

Get News Alerts by Email

May 13, 2024

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
May 06, 2024

AbbVie to Present at the Bank of America Securities Healthcare Conference
April 26, 2024

AbbVie Reports First-Quarter 2024 Financial Results
April 04, 2024

AbbVie to Host First-Quarter 2024 Earnings Conference Call
March 07, 2024

AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference

Show per page

Our history

Explore where we've been and how we continue to go beyond medicine to make a remarkable impact. Learn more

Sustainability

Our commitment to science is a commitment to better our society. Read our 2024 ESG report

Ratings and recognition

We've been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more

Annual report

See our latest 2024 Annual Report on Form 10-K. Learn more

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?